Revance Therapeutics, Inc.

DAXXIFY

Manufacturer:

Revance Therapeutics, Inc.

Daxxify HCPCS:

C9160

HCPCS Code Descriptor:

Injection, daxibotulinumtoxina-lanm, 1 unit

Category:

C Code

Daxxify NDCs:

72960-0112-01

Primary Type:

Botulinum Toxin

Generic/Specialty Status:

Single-Source

Route of Administration:

Intramuscular

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Daxxify:

DAXXIFY is a Botulinum Toxin drug manufactured by Revance Therapeutics, Inc. and administered via the Intramuscular route of administration. The C Code: C9160 is aligned to the drug DAXXIFY.

ACCESS PRICING AND MORE BY REGISTERING

C9160 Added Date:

January 1, 2024

C9160 Effective Date:

January 1, 2024

C9160 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Daxxify billing and coding information.
Our team did not identify a source for Daxxify patient assistance information. Please reach out to our team if you feel that this is a mistake.
DAXXIFY prescribing information can be found at the link below:
Information regarding DAXXIFY’s side effects can be found at MedlinePlus